Physician profile
Melissa Melott
NPI 1417168816
$4,763.95
in general payments reported to CMS, 2019-2025
22 companies · $871 in 2025
The $871 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.77 · 2020: $67.68 · 2021: $915 · 2022: $1,103 · 2023: $714 · 2024: $1,030 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $844.31 | 2020-2025 | Wavelight Refractive Suite, Clareon Panoptix Pro, Rocklatan |
| Glaukos Corporation | $693.06 | 2019-2024 | Idose, Radius, Photrexa |
| Rxsight INC | $504.97 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $401.00 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Lensar, INC. | $367.37 | 2021 | |
| Allergan, INC. | $271.66 | 2021-2022 | |
| Abbvie INC. | $243.11 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $201.34 | 2019-2023 | |
| Harrow Eye, LLC | $200.50 | 2025 | Vevye |
| Dompe US, INC. | $141.17 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $140.56 | 2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $131.04 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $127.36 | 2023 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $126.76 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $124.26 | 2024 | Syfovre |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $82.52 | 2021 | |
| Oyster Point Pharma, INC. | $55.43 | 2022-2024 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $36.80 | 2024 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $24.16 | 2021 | |
| Biotissue Holdings INC. | $17.47 | 2021 | |
| Shire North American Group INC | $14.84 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Melott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.